ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cytokines and Soluble Mediators in Immunity

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1579896

This article is part of the Research TopicBiomarker-Driven Strategies for Personalized Management of Systemic Inflammatory Response SyndromeView all 6 articles

Human saliva exerts strong type-dependent effects on adenovirus infectivity

Provisionally accepted
Erwan  SallardErwan Sallard*Wenli  ZhangWenli ZhangNikita  ChilakamarriNikita ChilakamarriSetareh  FarzanehkariSetareh FarzanehkariInga  M.C. SeutheInga M.C. SeutheAnja  EhrhardtAnja EhrhardtMalik  AydinMalik Aydin*
  • Witten/Herdecke University, Witten, North Rhine-Westphalia, Germany

The final, formatted version of the article will be published soon.

The development of mucosal adenovirus (Ad) vaccine vectors is considered one of the next frontiers to protect vulnerable patients from respiratory and gastrointestinal pathogens. An efficient delivery to or through the oral cavity necessitates a thorough understanding of Ad interactions with saliva for oral, buccal or sublingual vaccine delivery, which could additionally prove instrumental in the containment of natural Ad infections but remains unexplored. Therefore, we investigated the influence of saliva on Ad infectivity, emphasizing its intrinsic antiviral role against particular Ad types in various epithelial cell cultures.A saliva pool was created from healthy donors (n=16) and incubated with ChAdOx1 or human Ads from 20 different types prior to infection of human immortalized epithelial cells. All human Ads used were replication-competent and expressed a GLN cassette containing a green-fluorescent protein, nano-luciferase, and neomycin resistance. Loss-of-function experiments were conducted by immunoprecipitation or enzymatic digestion of specific saliva components to decipher related mechanisms.Temporal and inter-individual variability in saliva samples were observed, validating the use of a saliva pool to represent the population. Saliva strongly influenced Ad infectivity, in general through inhibiting species B types and enhancing species D and E Ads, that include the vaccine vector platforms Ad26 and ChAdOx1. Interestingly, Ad20 presented the highest infectivity enhancement, as well as superior to average salivary mucus crossing rates. Furthermore, saliva immunoglobulins and human neutrophil peptides marginally influenced the Ad infectivity, while sialic acid inhibited all tested Ad types. Saliva may have a protective role against infection by certain types of Ads. This discovery highlights a potential limitation in the efficacy of next-generation oral Ad vaccine vectors. Consequently, our study underscores the importance of identifying and utilizing saliva-resistant Ad vectors to optimize Ad-based vaccination strategies.

Keywords: Human adenovirus, Saliva, Oral Vaccine, mucosal immunity, Mucosal delivery, epithelium infection

Received: 19 Feb 2025; Accepted: 19 May 2025.

Copyright: © 2025 Sallard, Zhang, Chilakamarri, Farzanehkari, Seuthe, Ehrhardt and Aydin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Erwan Sallard, Witten/Herdecke University, Witten, 58448, North Rhine-Westphalia, Germany
Malik Aydin, Witten/Herdecke University, Witten, 58448, North Rhine-Westphalia, Germany

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.